Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Chymase-Dependent Conversion of Big Endothelin-1 in the Mouse in Vivo

Elie Simard, Denan Jin, Shinji Takai, Mizuo Miyazaki, Isabelle Brochu and Pedro D'Orléans-Juste
Journal of Pharmacology and Experimental Therapeutics February 2009, 328 (2) 540-548; DOI: https://doi.org/10.1124/jpet.108.142992
Elie Simard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denan Jin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinji Takai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mizuo Miyazaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Brochu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro D'Orléans-Juste
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The aim of this study was to identify the role of chymase in the conversion of exogenously administered Big endothelin-1 in the mouse in vivo. Real-time polymerase chain reaction analysis detected mRNA of mucosal mast cell chymases 4 and 5, endothelin-converting enzyme 1a, and neutral endopeptidase 24.11 in pulmonary, cardiac, and aorta homogenates derived from C57BL/6J mice, with the latter tissue expressing the highest levels of both chymase isoforms. Furthermore, hydrolysis of a fluorogenic peptide substrate, Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin, was sensitive to the chymase inhibitors Suc-Val-Pro-PheP(OPh)2 (200 μM) and chymostatin [(S)-1-carboxy-2-phenylethyl]-carbamoyl-α-[2-iminohexahydro-4(S)-pyrimidyl]-(S)-Gly-X-Phe-al, where X can be the amino acid Leu, Val, or Ile) (100 μM) in supernatants extracted from the same tissue homogenates. In anesthetized mice, Big endothelin-1, endothelin-1 (1–31), and endothelin-1 triggered pressor responses (ED50s, 0.67, 0.89, and 0.16 nmol/kg) that were all reduced or potentiated by selective endothelin ETA or ETB receptor antagonists, respectively, BQ-123 (cyclo[d-Asp-Pro-d-Val-Leu-d-Trp]) or BQ-788 (N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine sodium salt), each at 1 mg/kg. The pressor responses to big endothelin-1 were significantly reduced by the neutral endopeptidase inhibitor thiorphan (dl-3-mercapto-2-benzylpropanoylglycine) (1 mg/kg) or the endothelin-converting enzyme inhibitor CGS 35066 [α-[(S)-(phosphonomethyl)amino]-3-dibenzofuranopropanoic acid] (0.1 mg/kg). In contrast, the responses to endothelin-1 (1–31) were abolished by thiorphan but unaffected by CGS 35066. In addition, Suc-Val-Pro-PheP(OPh)2 (20–40 mg/kg) reduced, by more than 60%, the hemodynamic response to big endothelin-1 but not to endothelin-1 (1–31) and endothelin-1. Finally, intravenous administration of big endothelin-1 induced Suc-Val-Pro-PheP-(OPh)2-sensitive increases in plasma-immunoreactive levels of endothelin-1 (1–31) and endothelin-1. The present study suggests that chymase plays a pivotal role in the conversion and cardiovascular properties of big endothelin-1 in vivo.

Footnotes

  • This work was supported by the Canadian Institutes for Health Research and by the Etienne Lebel Clinical Research Center.

  • The authors of the present manuscript declare that there are no financial links, including consultancies with manufacturers of material or devices described in the article, and no links to the pharmaceutical industry or regulatory agencies or any other potential conflicts of interest.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.108.142992.

  • ABBREVIATIONS: ECE, endothelin-converting enzyme; ET, endothelin; phosphoramidon, N-(α-rhamno-pyranosyl-oxy-hydroxy-phosphinyl)-Leu-Trp disodium salt; NEP, neutral endopeptidase; Big ET-1 (1–38), big endothelin-1 (1–38); chymostatin, [(S)-1-carboxy-2-phenylethyl]-carbamoyl-α-[2-iminohexahydro-4(S)-pyrimidyl]-(S)-Gly-X-Phe-al, where X can be the amino acid Leu, Val, or Ile; mMCP, murine mast cell protease; PCR, polymerase chain reaction; F, forward; R, reverse; MCA, 7-amino-4-methylcoumarin; MAP, mean arterial pressure; HR, heart rate; BQ-123, cyclo(d-Asp-Pro-d-Val-Leu-d-Trp; BQ-788, N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine sodium salt; thiorphan, dl-3-mercapto-2-benzylpropanoylglycine; CGS 35066, α-[(S)-(phosphonomethyl)amino]-3-dibenzofuranopropanoic acid; HPLC, high-pressure liquid chromatography; RIA, radioimmunoassay; EIA, enzymatic immunoassay; IR, immunoreactive; PBS, phosphate-buffered saline; NK-2301, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide; SUN-C8257, 3-[(3-amino-4-carboxy)phenylsulfonyl]-7-chloroquinazoline-2,4(1H,3H)-dione; TY-51184, 2-[4-(5-fluoro-3-methylbenzo-[b]thiophen-2-yl)sulfonamide-3-methanesulfonylphenyl] oxazole-4-carboxylic acid; IRL 1620, Suc-[Glu9,Ala11,15]-endothelin-1(8-21).

    • Received July 5, 2008.
    • Accepted November 4, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 376 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 376, Issue 3
1 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Chymase-Dependent Conversion of Big Endothelin-1 in the Mouse in Vivo
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Chymase-Dependent Conversion of Big Endothelin-1 in the Mouse in Vivo

Elie Simard, Denan Jin, Shinji Takai, Mizuo Miyazaki, Isabelle Brochu and Pedro D'Orléans-Juste
Journal of Pharmacology and Experimental Therapeutics February 1, 2009, 328 (2) 540-548; DOI: https://doi.org/10.1124/jpet.108.142992

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCARDIOVASCULAR

Chymase-Dependent Conversion of Big Endothelin-1 in the Mouse in Vivo

Elie Simard, Denan Jin, Shinji Takai, Mizuo Miyazaki, Isabelle Brochu and Pedro D'Orléans-Juste
Journal of Pharmacology and Experimental Therapeutics February 1, 2009, 328 (2) 540-548; DOI: https://doi.org/10.1124/jpet.108.142992
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Effects of four COVID-19 drugs on hERG channels
  • Improved Assessment of Cardiovascular Safety Data
  • β3-Agonist Improves Myocardial Stiffness
Show more Cardiovascular

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics